The number of pharmaceutical products entering the market has declined in the last decade. With the economic downturn and increasing threat from generic companies, pharmaceutical companies have never been under greater pressure to develop new innovative drugs. Many pharmaceutical and biotechnology companies are now searching for effective strategies to improve hit-to-lead conversion and to identify unsuccessful compounds early in the development process.
SMi’s Drug Design Conference will aim to address many of the challenging issues faced by the pharmaceutical industry in drug design. Key selected industry experts will provide you with timely and up-to-date information on many areas of drug design.
20 to 21 February 2012
London, London, United Kingdom
Conference Details
